Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

Date:

Tilray Brands, Inc.

New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG

COLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its medical cannabis division, Tilray Medical, the global leader in medical cannabis, enthusiastically welcomes the opening of the German medical cannabis market and the positive paradigm shift in German drug policy. Today’s landmark passage of the German Medical Cannabis Act represents a significant step forward and puts public health in the spotlight while providing patients with easier access to high-quality cannabis medicines produced in Germany.

Tilray Medical’s Chief Strategy Officer and Head of International Denise Faltischek comments: “The decision to open up…

Read more…

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Tampa RV giant Lazydays to delist from Nasdaq

Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...

Granite Geek: New Hampshire might get access to ‘balcony solar’

I had solar panels put on my roof six...

TSX Today: What to Watch for in Stocks on Monday, November 10

Despite firm gold and silver prices, Canadian stocks...

While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!

As market-wide fear grips the sector, the Binance Coin...